Risk group-4 virus emergent threats.

Paul Shapshak, Seetharaman Balaji, Charurut Somboonewit, John T Sinnott, Francesco Chiappelli

Abstract readEditorial

In one paragraph

Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Paul ShapshakDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida 33606, USA.

Seetharaman BalajiDepartment of Biotechnology, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.

Charurut SomboonewitDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida 33606, USA.

John T SinnottDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida 33606, USA.

Francesco ChiappelliUCLA Center for the Health Sciences, Los Angeles, California 90095, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several Filovirus outbreaks occurred during 2021-2025 in Africa. The case fatality ratios (CFRs) were elevated as expected for these viruses. After outbreaks were termed terminated, nonetheless, due to virus pathogenicity and transmissibility, epidemics continued unabated. To mitigate future outbreaks and bolster pandemic preparedness, collaborative global strategies should continue and expand.

Indexed as

Africabiosafety laboratory (BSL)-4case fatality rateCDCecologyemergent virusfilovirus (Ebola, Marburg and Sudan viruses)global warmingNIAIDNIHreservoirrisk group 4 (rg-4) virus pathogensvectorvirulenceWorld Health Organization (WHO)

Identifiers

PMID40636188

DOI10.6026/973206300210721

PMCPMC12236526

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.